Synonym
Disulergine; CH 29717; CH 29-717; CM 29717
IUPAC/Chemical Name
N,N-Dimethyl-N'-((8 alpha)-6-methylergolin-8-yl)sulfamide
InChi Key
VUEGYUOUAAVYAS-JGGQBBKZSA-N
InChi Code
InChI=1S/C17H24N4O2S/c1-20(2)24(22,23)19-12-8-14-13-5-4-6-15-17(13)11(9-18-15)7-16(14)21(3)10-12/h4-6,9,12,14,16,18-19H,7-8,10H2,1-3H3/t12-,14+,16+/m0/s1
SMILES Code
O=S(N[C@@H](C[C@@]12[H])CN(C)[C@]1([H])CC3=CNC4=C3C2=CC=C4)(N(C)C)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
348.47
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Spada A, Bassetti M, Reza-Elahi F, Arosio M, Gil-Del-Alamo P, Vallar L. Differential transduction of dopamine signal in different subtypes of human growth hormone-secreting adenomas. J Clin Endocrinol Metab. 1994 Feb;78(2):411-7. PubMed PMID: 7906281.
2: Spada A, Sartorio A, Bassetti M, Pezzo G, Giannattasio G. In vitro effect of dopamine on growth hormone (GH) release from human GH-secreting pituitary adenomas. J Clin Endocrinol Metab. 1982 Oct;55(4):734-40. PubMed PMID: 7107817.
3: Markó M. Dopamine agonistic potency of two novel prolactin release-inhibiting ergolines. Eur J Pharmacol. 1984 Jun 1;101(3-4):263-6. PubMed PMID: 6468500.
4: Flückiger E, Briner U, Bürki HR, Marbach P, Wagner HR, Doepfner W. Two novel prolactin release-inhibiting 8 alpha-amino-ergolines. Experientia. 1979 Dec 15;35(12):1677-8. PubMed PMID: 520501.
5: Spada A, Bassetti M, Martino E, Giannattasio G, Beck-Peccoz P, Sartorio A, Vallar L, Baschieri L, Pinchera A, Faglia G. In vitro studies on TSH secretion and adenylate cyclase activity in a human TSH-secreting pituitary adenoma. Effects of somatostatin and dopamine. J Endocrinol Invest. 1985 Jun;8(3):193-8. PubMed PMID: 2863299.
6: Nielsen EB, Randrup K, Andersen PH. Amphetamine discrimination: effects of dopamine receptor agonists. Eur J Pharmacol. 1989 Jan 31;160(2):253-62. PubMed PMID: 2569406.
7: Grossman A, Yeo T, Delitala G, Hathway NR, Besser GM. Two new dopamine agonists that are long acting in vivo but short acting in vitro. Clin Endocrinol (Oxf). 1980 Dec;13(6):595-9. PubMed PMID: 7226572.
8: Prysor-Jones RA, Jenkins JS. Effect of bromocriptine, ergotamine and other ergot alkaloids on the hormone secretion and growth of a rat pituitary tumour. J Endocrinol. 1980 Jul;86(1):147-53. PubMed PMID: 7430884.
